Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Bernstein initiated coverage of Biogen Inc (NASDAQ:BIIB) with a “Market-Perform” rating and a price target of $160 as it noted uncertainty around the company’s near-term growth prospects despite ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.